{"title":"Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma.","authors":"Cancan Lu, Ming-Zhe Zhao","doi":"10.7754/Clin.Lab.2024.240910","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although several chimeric antigen receptor T cells (CAR T) targeting CD19 are curative for patients with relapsed/refractory(R/R) B-cell lymphoma, but the clinical safety and efficacy of this CAR T therapy remain unclear. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T therapy.</p><p><strong>Methods: </strong>A patient with R/R follicular lymphoma was diagnosed with secondary myelodysplastic syndrome (s-MDS) after CD19 CAR T therapy. We also provided a review of recently published literature concerning the risk of secondary myeloid neoplasms (SMN) following CAR T therapy.</p><p><strong>Results: </strong>The patient had secondary MDS after CD19 CAR T therapy. She received active treatment for nearly one year and then she died.</p><p><strong>Conclusions: </strong>The case illustrated the onset and progression of SMN after CD19 CAR T therapy in patients with R/R B-cell lymphoma and provides useful information of this uncommon later event.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 2","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240910","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Although several chimeric antigen receptor T cells (CAR T) targeting CD19 are curative for patients with relapsed/refractory(R/R) B-cell lymphoma, but the clinical safety and efficacy of this CAR T therapy remain unclear. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T therapy.
Methods: A patient with R/R follicular lymphoma was diagnosed with secondary myelodysplastic syndrome (s-MDS) after CD19 CAR T therapy. We also provided a review of recently published literature concerning the risk of secondary myeloid neoplasms (SMN) following CAR T therapy.
Results: The patient had secondary MDS after CD19 CAR T therapy. She received active treatment for nearly one year and then she died.
Conclusions: The case illustrated the onset and progression of SMN after CD19 CAR T therapy in patients with R/R B-cell lymphoma and provides useful information of this uncommon later event.
期刊介绍：
Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
